全文获取类型
收费全文 | 336篇 |
免费 | 20篇 |
国内免费 | 2篇 |
专业分类
儿科学 | 1篇 |
妇产科学 | 2篇 |
基础医学 | 24篇 |
临床医学 | 23篇 |
内科学 | 169篇 |
皮肤病学 | 2篇 |
神经病学 | 29篇 |
特种医学 | 27篇 |
外科学 | 43篇 |
综合类 | 1篇 |
预防医学 | 15篇 |
眼科学 | 1篇 |
药学 | 2篇 |
肿瘤学 | 19篇 |
出版年
2023年 | 1篇 |
2020年 | 2篇 |
2018年 | 3篇 |
2017年 | 1篇 |
2016年 | 4篇 |
2015年 | 6篇 |
2014年 | 6篇 |
2013年 | 9篇 |
2012年 | 30篇 |
2011年 | 28篇 |
2010年 | 9篇 |
2009年 | 10篇 |
2008年 | 23篇 |
2007年 | 26篇 |
2006年 | 40篇 |
2005年 | 23篇 |
2004年 | 29篇 |
2003年 | 54篇 |
2002年 | 18篇 |
2001年 | 22篇 |
2000年 | 3篇 |
1999年 | 1篇 |
1997年 | 3篇 |
1993年 | 2篇 |
1992年 | 2篇 |
1990年 | 1篇 |
1983年 | 1篇 |
1964年 | 1篇 |
排序方式: 共有358条查询结果,搜索用时 15 毫秒
1.
2.
Church J Lowry A Simmang C;Standards Task Force;American Society of Colon Rectal Surgeons 《Diseases of the colon and rectum》2001,44(10):1404-1412
It should be recognized that these guidelines should not be deemed inclusive of all proper methods of care or exclusive of methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding the propriety of any specific procedure must be made by the physician in light of all of the circumstances presented by the individual patient.
Prepared By The Standards Task Force The American Society of Colon and Rectal Surgeons 相似文献
3.
Bone Marrow Assessment in Asymptomatic IgM Monoclonal Gammopathies – Reply to Varettoni et al
下载免费PDF全文
![点击此处可从《British journal of haematology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Roger G. Owen Guy Pratt Rebecca L. Auer Rita Flatley Charalampia Kyriakou Michael P. Lunn Francis Matthey Helen McCarthy Feargal P. McNicholl Saad M. Rassam Simon D. Wagner Matthew Streetly Shirley D'Sa the British Committee for Standards in Haematology 《British journal of haematology》2015,168(2):302-303
4.
5.
6.
Pavord S Myers B Robinson S Allard S Strong J Oppenheimer C;British Committee for Standards in Haematology 《British journal of haematology》2012,156(5):588-600
Iron deficiency is the most common deficiency state in the world, affecting more than 2 billion people globally. Although it is particularly prevalent in less-developed countries, it remains a significant problem in the developed world, even where other forms of malnutrition have already been almost eliminated. Effective management is needed to prevent adverse maternal and pregnancy outcomes, including the need for red cell transfusion. The objective of this guideline is to provide healthcare professionals with clear and simple recommendations for the diagnosis, treatment and prevention of iron deficiency in pregnancy and the postpartum period. This is the first such guideline in the UK and may be applicable to other developed countries. Public health measures, such as helminth control and iron fortification of foods, which can be important to developing countries, are not considered here. The guidance may not be appropriate to all patients and individual patient circumstances may dictate an alternative approach. 相似文献
7.
Jones G Parry-Jones N Wilkins B Else M Catovsky D;British Committee for Standards in Haematology 《British journal of haematology》2012,156(2):186-195
The British Committee for Standards in Haematology first produced guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant in 2000. This revision updates those guidelines and covers the areas of diagnosis, treatment and assessment of response to therapy. 相似文献
8.
Dignan FL Amrolia P Clark A Cornish J Jackson G Mahendra P Scarisbrick JJ Taylor PC Shaw BE Potter MN;Haemato-oncology Task Force of British Committee for Standards in Haematology;British Society for Blood Marrow Transplantation 《British journal of haematology》2012,158(1):46-61
A joint working group established by the Haemato-oncology subgroup of the British Committee for Standards in Haematology (BCSH) and the British Society for Bone Marrow Transplantation (BSBMT) has reviewed the available literature and made recommendations for the diagnosis and management of chronic graft-versus-host disease (GvHD). This guideline includes recommendations for the diagnosis and staging of chronic GvHD as well as primary treatment and options for patients with steroid-refractory disease. The goal of treatment should be the effective control of GvHD while minimizing the risk of toxicity and relapse. 相似文献
9.
Diagnosis and management of acute graft-versus-host disease 总被引:1,自引:0,他引:1
Dignan FL Clark A Amrolia P Cornish J Jackson G Mahendra P Scarisbrick JJ Taylor PC Hadzic N Shaw BE Potter MN;Haemato-oncology Task Force of British Committee for Standards in Haematology;British Society for Blood Marrow Transplantation 《British journal of haematology》2012,158(1):30-45
A joint working group established by the Haemato-oncology subgroup of the British Committee for Standards in Haematology (BCSH) and the British Society for Bone Marrow Transplantation (BSBMT) has reviewed the available literature and made recommendations for the diagnosis and management of acute graft-versus-host disease. This guideline includes recommendations for the diagnosis and grading of acute graft-versus-host disease as well as primary treatment and options for patients with steroid-refractory disease. The goal of treatment should be effective control of graft-versus-host disease while minimizing risk of toxicity and relapse. 相似文献
10.
Kiely PD Deighton C Dixey J Ostör AJ;British Society for Rheumatology Standards Guidelines Audit Working Group 《Rheumatology (Oxford, England)》2012,51(1):24-31
In England and Wales, the National Institute for Health and Clinical Excellence (NICE) has provided guidance [technology appraisals (TAs) 130, 186, 195, 198 and 225] on the use of biologic drugs for the treatment of RA. This is based on an analysis of efficacy, safety and cost-effectiveness, and has resulted in a complex management pathway that restricts freedom to prescribe biologics according to their licensed indications. Specifically, TNF antagonists are the only class of biologics that can be used first line in DMARD-inadequate responders, and only in patients with a persistent 28-joint DAS score of ≥5.1. Alternative biologic agents are denied to those with contraindications to anti-TNF drugs and are also not supported following intolerance to TNF antagonists. Rituximab is the only class of biologic permitted after TNF antagonist inefficacy, in the absence of a contraindication to its use, whereas abatacept and tocilizumab are licensed and may be a more efficacious choice at this stage in some patient groups. Furthermore, for patients who demonstrate sequential inadequate responses, treatment is restricted to one TNF antagonist, rituximab and tocilizumab, whereas abatacept is only a permitted choice when rituximab is contraindicated or has been withdrawn because of an adverse event. In this review, we discuss the treatment algorithm published by NICE, and suggest alternatives where perceived deficiencies exist. 相似文献